Rep. Lisa C. McClain Sells Off Shares of Sanofi (NASDAQ:SNY)

Key Points

• Representative Lisa C. McClain sold shares of Sanofi (NASDAQ:SNY) worth between $1,001 and $15,000 on September 11th, as disclosed in a filing made on October 22nd.
• Sanofi's stock is currently down 0.9% and has a market capitalization of $121.60 billion with a P/E ratio of 11.90.
• Recent performance showed Sanofi missed earnings expectations, reporting $0.90 EPS compared to the analysts' consensus estimate of $0.96, while its revenue was down 7.0% year-over-year.

Representative Lisa C. McClain (R-Michigan) recently sold shares of Sanofi NASDAQ: SNY. In a filing disclosed on October 22nd, the Representative disclosed that they had sold between $1,001 and $15,000 in Sanofi stock on September 11th. The trade occurred in the Representative's "CHARLES SCHWAB BROKERAGE ACCOUNT 924" account.

Representative Lisa C. McClain also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of FMC NYSE: FMC on 9/25/2025.
• Sold $1,001 - $15,000 in shares of Merit Medical Systems NASDAQ: MMSI on 9/25/2025.
• Purchased $1,001 - $15,000 in shares of Darden Restaurants NYSE: DRI on 9/25/2025.
• Purchased $1,001 - $15,000 in shares of ASML NASDAQ: ASML on 9/25/2025.
• Purchased $1,001 - $15,000 in shares of Kenvue NYSE: KVUE on 9/25/2025.
• Sold $1,001 - $15,000 in shares of Beacon Financial NYSE: BBT on 9/25/2025.
• Sold $1,001 - $15,000 in shares of British American Tobacco NYSE: BTI on 9/25/2025.
• Purchased $1,001 - $15,000 in shares of Rollins NYSE: ROL on 9/25/2025.
• Purchased $1,001 - $15,000 in shares of SAP NYSE: SAP on 9/25/2025.
• Purchased $1,001 - $15,000 in shares of MGP Ingredients NASDAQ: MGPI on 9/25/2025.

Sanofi Stock Down 0.9%

SNY opened at $49.52 on Friday. Sanofi has a one year low of $44.62 and a one year high of $60.12. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.94 and a current ratio of 1.27. The stock's fifty day moving average is $48.61 and its 200-day moving average is $49.54. The company has a market capitalization of $121.60 billion, a PE ratio of 11.90, a P/E/G ratio of 1.21 and a beta of 0.51.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing analysts' consensus estimates of $0.96 by ($0.06). Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The firm had revenue of $11.34 billion during the quarter, compared to the consensus estimate of $9.91 billion. During the same period in the prior year, the firm posted $1.73 EPS. The firm's quarterly revenue was down 7.0% on a year-over-year basis. On average, equities analysts predict that Sanofi will post 4.36 EPS for the current fiscal year.

Hedge Funds Weigh In On Sanofi

Large investors have recently made changes to their positions in the business. Brighton Jones LLC increased its stake in Sanofi by 52.6% in the 4th quarter. Brighton Jones LLC now owns 5,420 shares of the company's stock valued at $261,000 after buying an additional 1,869 shares during the period. GAMMA Investing LLC increased its stake in shares of Sanofi by 58.7% in the first quarter. GAMMA Investing LLC now owns 6,057 shares of the company's stock worth $336,000 after acquiring an additional 2,241 shares during the last quarter. Cambridge Investment Research Advisors Inc. increased its stake in shares of Sanofi by 1.0% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 33,328 shares of the company's stock worth $1,848,000 after acquiring an additional 318 shares during the last quarter. Oppenheimer Asset Management Inc. increased its stake in shares of Sanofi by 22.5% in the first quarter. Oppenheimer Asset Management Inc. now owns 155,380 shares of the company's stock worth $8,617,000 after acquiring an additional 28,569 shares during the last quarter. Finally, Oppenheimer & Co. Inc. increased its stake in shares of Sanofi by 3.6% in the first quarter. Oppenheimer & Co. Inc. now owns 8,640 shares of the company's stock worth $479,000 after acquiring an additional 298 shares during the last quarter. Institutional investors and hedge funds own 14.04% of the company's stock.

Wall Street Analyst Weigh In

SNY has been the topic of a number of research reports. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a "hold" rating to a "buy" rating in a report on Tuesday, September 2nd. JPMorgan Chase & Co. raised Sanofi from a "neutral" rating to an "overweight" rating in a report on Friday, August 8th. Barclays reaffirmed an "overweight" rating on shares of Sanofi in a report on Wednesday, July 2nd. Wall Street Zen raised Sanofi from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Finally, Weiss Ratings reaffirmed a "hold (c)" rating on shares of Sanofi in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, Sanofi presently has an average rating of "Buy" and an average target price of $62.67.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan's 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027. McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan's 9th Congressional District. She declared candidacy for the 2026 election. Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor's degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.